 |
|
|
|
|
|
|
Nateglinide
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Pharmacology
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Dosage
Nateglinide is delivered in 60mg & 120mg tablet form.
| Oral antidiabetic drugs and Insulin analogs (A10) |
|---|
| Biguanides | Metformin |
|---|
| Sulfonylureas | Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide |
|---|
| Alpha-glucosidase inhibitors | Acarbose, Miglitol, Voglibose |
|---|
| Thiazolidinediones (TZD) | Pioglitazone, Rosiglitazone, Troglitazone |
|---|
| Meglitinides | Nateglinide, Repaglinide, Mitiglinide |
|---|
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | Saxagliptin, Sitagliptin, Vildagliptin |
|---|
| Glucagon-like peptide-1 analog | Exenatide |
|---|
| Insulin analogs | fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), intermediate-acting (NPH insulin), long acting (Insulin glargine, Insulin detemir) |
|---|
|
| |
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nateglinide". A list of authors is available in Wikipedia.
|
Additional information matching your search term
Additional information was found matching your search for Nateglinide.
|
|
|
|
|
Top